最新临床试验：阿维鲁单抗联合或不联合西妥昔单抗治疗晚期皮肤鳞癌

这是经美国国家癌症研究所批准的一项多中心随机对照 II期临床试验，目的是研究阿维鲁单抗联合或不联合西妥昔单抗治疗皮肤鳞状细胞癌患者的效果，该鳞状细胞癌已经扩散到身体的其他部位（晚期）。单克隆抗体的免疫治疗，如阿维鲁单抗和西妥昔单抗，可能有助于机体免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散能力。

该临床试验在全美226家医院进行开展。

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Trial IDs